Evaluation of the Safety and Efficacy of Methylone for the Treatment of PTSD IMPACT-2 (Investigation of Methylone for PTSD
This study is completed in the United States, in Australia, and in the United Kingdom. It is testing Evaluation of the Safety and Efficacy of Methylone for the Treatment of PTSD IMPACT-2 (Investigation of Methylone for PTSD.
PTSDDrugFrom 18 Years to 70 Years
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Then choose your country and confirm availability with each study site.
In plain English
Key information made simple
What is this study testing?
This study is testing whether the Safety and Efficacy of Methylone may be useful for adults experiencing ptsd.
What would participation involve?
Participants may receive the Safety and Efficacy of Methylone, attend study visits with the research team. The registry lists locations in Australia, in the United Kingdom, and in the United States.
Who is it mainly for?
This study appears to be mainly for adults with ptsd.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.
Your next step
Check the study details
Check the official source, then confirm these points with the research team.
Where are visits, can any be remote, and how much time is needed?
Costs and support
What costs, reimbursement or compensation apply?
Before joining
Questions to ask before joining
What are the exact eligibility criteria, and what could exclude someone?
How many visits, assessments, or follow-ups are expected, and over what period?
What risks, side effects, practical burdens, or alternatives should be understood first?
Who should be contacted to confirm locations, timing, compensation, and next steps?
Study clarity
Things to check before joining
Study start dateStarted: April 4, 2024
Recruitment status
Completed
Enrollment listed in the registry
62
Sponsor
Transcend Therapeutics
Sponsor type
Biotech company
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States, Australia, United Kingdom
Age range
From 18 Years to 70 Years
Official registry ID
NCT06215261
Official title
An Evaluation of the Safety and Efficacy of Methylone for the Treatment of PTSD IMPACT-2 (Investigation of Methylone for Post-Traumatic Stress Disorder [PTSD])
Ask HopeStage to help me review this study
This record does not confirm open recruitment. We can help you understand it and explore other studies.
Study ID: NCT06215261. We help you review the study, but cannot decide medical eligibility.
Check recruitment and locations
Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.
The overall study status can differ from each site's status. Open a country to see its locations and their registry status.
Australia · 3 sites
Swinburne University of Technology
Hawthorn, Victoria
Site status: Not listed — confirm with the team
Ramsay Clinic Albert Road
Melbourne, Victoria
Site status: Not listed — confirm with the team
Monarch Mental Health Group
Melbourne, Victoria
Site status: Not listed — confirm with the team
United Kingdom · 1 site
Clerkenwell Health
London
Site status: Not listed — confirm with the team
United States · 8 sites
Segal Trials
Lauderhill, Florida
Site status: Not listed — confirm with the team
Accel Research
Maitland, Florida
Site status: Not listed — confirm with the team
CNS Healthcare
Orlando, Florida
Site status: Not listed — confirm with the team
Uptown Clinical Research
Chicago, Illinois
Site status: Not listed — confirm with the team
Sunstone Medical
Rockville, Maryland
Site status: Not listed — confirm with the team
Redbird Research LLC
Las Vegas, Nevada
Site status: Not listed — confirm with the team
Numinus
Draper, Utah
Site status: Not listed — confirm with the team
Seattle NTC
Bellevue, Washington
Site status: Not listed — confirm with the team
In practice
For you
Participation may contribute to research. Personal benefit is not guaranteed.
Ask the research team to explain the activities, time commitment, and follow-up involved.
Study sites are listed. Confirm the relevant site and any travel before making plans.
Important
Not medical advice
Information from public sources.
Are you the study sponsor? Contact us to update this page: hi@hopestage.com
FAQ
Questions about this study
What is this study trying to understand?
Based on the public registry summary, this study is trying to understand: This study is evaluating the safety and efficacy of methylone in adults with PTSD. The study is conducted in two parts. * Part A is open-label and will enroll up to 15 participants with PTSD * Part B is randomized (1:1:1), single-blind and will enroll up to 45 participants with. The study team can confirm the exact objective and what it means for you.
Does this study involve a medication?
This appears to be a medication / drug study involving Methylone. Phase 2 studies usually explore whether the intervention may work, while continuing to monitor safety.
Who might this study be for?
This study may concern people with ptsd; age range: From 18 Years to 70 Years. The criteria appear fairly broad, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What side effects, interactions, or treatment changes should I check?
If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by Transcend Therapeutics, which appears to be a biotech company. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Explore other studies
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
